Speaking From Experience: Real-World Evidence in First-Line and Subsequent Treatments in Locally Advanced or Metastatic Urothelial Carcinoma

Speaking from Experience: Real-World Evidence in First-Line and Subsequent Treatments in Locally Advanced or Metastatic Urothelial Carcinoma

The post Speaking from Experience: Real-World Evidence in First-Line and Subsequent Treatments in Locally Advanced or Metastatic Urothelial Carcinoma appeared first on European Medical Journal.

Short-term outcomes of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: Real-world use in multicenter cohort regardless of cisplatin eligibility

This study aimed to evaluate the short-term efficacy and safety of enfortumab vedotin plus pembrolizumab (EV + P) as a first-line systemic therapy for patients with advanced urothelial carcinoma (UC) in real-world practice, with a focus on cisplatin (CDDP) eligibility. Seventy-si...